Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.

Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.

[1]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[2]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[3]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[4]  S. Solomon,et al.  Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. , 2006, Heart rhythm.

[5]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[6]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[7]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[8]  Helmut Baumgartner,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, European journal of heart failure.

[9]  T. Vassiliades,et al.  Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. , 2012, The Annals of thoracic surgery.

[10]  L. Jordaens,et al.  The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. , 2012, Journal of the American College of Cardiology.

[11]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[12]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[13]  B. Turnbull,et al.  Group Sequential Methods with Applications to Clinical Trials , 1999 .

[14]  P. Erwin,et al.  Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients. , 2013, The Annals of thoracic surgery.

[15]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[16]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[17]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[18]  A. Moss,et al.  Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. , 2008, Journal of the American College of Cardiology.

[19]  Daniel R. Frisch,et al.  16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. , 2011, Journal of the American College of Cardiology.

[20]  H. Huikuri,et al.  Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. , 2010, Heart rhythm.

[21]  S. Yusuf,et al.  Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.

[22]  H. Uno,et al.  The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction , 2010, European journal of heart failure.

[23]  L E Hinkle,et al.  Clinical Classification of Cardiac Deaths , 1982, Circulation.

[24]  William J. Hall,et al.  Sequential tests and estimators after overrunning based on maximum‐likelihood ordering , 2002 .

[25]  H. Wellens,et al.  Out-of-hospital cardiac arrest--the relevance of heart failure. The Maastricht Circulatory Arrest Registry. , 2003, European heart journal.

[26]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[27]  D. Todd,et al.  United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[28]  Karen L. Gunson,et al.  Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. , 2006, Journal of the American College of Cardiology.

[29]  Alexander H Maass,et al.  An entirely subcutaneous implantable cardioverter-defibrillator. , 2010, The New England journal of medicine.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  Sanjiv J. Shah,et al.  Mode of Death in Heart Failure With Preserved Ejection Fraction. , 2017, Journal of the American College of Cardiology.

[32]  Hung-Fat Tse,et al.  Sudden Cardiac Death After Myocardial Infarction in Type 2 Diabetic Patients With No Residual Myocardial Ischemia , 2012, Diabetes Care.

[33]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.